Back to Search
Start Over
Merck to develop biotech generics: its first copycat drug would compete with Amgen's Aranesp and is scheduled for launch in 2012
- Source :
- Wall Street Journal. Europe. Dec 10, 2008, A3
- Publication Year :
- 2008
-
Abstract
- Pharmaceutical giant Merck & Co. is planning to form a unit, Merck BioVentures, to develop generic versions of other pharmaceutical companies' top-selling biotech drugs. Merck will invest $1.5 billion in the new venture by 2015, and launch its first biotech drug in 2012 with at least five more releases planned by 2017.
- Subjects :
- Merck & Company Inc. -- Planning
Merck & Company Inc. -- Subsidiaries, divisions and units
Merck & Company Inc. -- Product development
Merck & Company Inc. -- Company forecasts
Merck & Company Inc. -- Investments
Generic drugs -- Product development
Biotechnology industry -- Product development
Pharmaceutical industry
Company business planning
Company business forecast/projection
Company investment
Banking, finance and accounting industries
Business
Business, international
Subjects
Details
- Language :
- English
- ISSN :
- 09219986
- Database :
- Gale General OneFile
- Journal :
- Wall Street Journal. Europe
- Publication Type :
- News
- Accession number :
- edsgcl.191404909